{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:04:57Z","timestamp":1784325897995,"version":"3.55.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To report clinical characteristics of exudative neovascular age-related macular degeneration in centenarian patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective, longitudinal study conducted in two retinal referral centers in Europe. Clinical characteristics of patients with neovascular age-related macular degeneration having at last follow-up at least 100 years and older were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-eight eyes from 14 patients (13 women), with a mean baseline age of 95.7 (SD 4.1) years and a mean follow-up duration of 89 months (39.9). The mean age at the last follow-up was 102.4 (1.7) years. Most eyes (86%) presented Type 1 macular neovascularization. At the last follow-up, best-corrected visual acuity was stable or improved in 57% of eyes, with a mean final best-corrected visual acuity of 53 letters (21.8), Snellen equivalent 20\/100. Eyes with better visual outcomes (&gt;50 letters) had significantly higher baseline best-corrected visual acuity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and thicker subfoveal choroidal thickness (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03). Macular hemorrhage (25%) and macular atrophy (53.6%) were associated with poorer best-corrected visual acuity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Centenarian patients with neovascular age-related macular degeneration can maintain vision with long-term anti-VEGF therapy. These findings underscore the need for tailored management strategies for the challenges faced by centenarians with neovascular age-related macular degeneration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004837","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:00:32Z","timestamp":1774450832000},"page":"1415-1423","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["CENTENARIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"46","author":[{"given":"Vittorio","family":"Capuano","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Fragiotta","sequence":"additional","affiliation":[{"name":"Ophthalmology Unit, Neurosciences, Mental Health, and Sense Organs (NESMOS) Department, Faculty of Medicine and Psychology, University of Rome Sapienza, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Abadou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Sacconi","sequence":"additional","affiliation":[{"name":"Division of Head and Neck, Ophthalmology Unit, University Vita-Salute IRCCS San Raffaele Scientific Institute, Milan, Italy;"},{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Miere","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Amoroso","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Souied","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-9581","authenticated-orcid":false,"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France;"},{"name":"Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia (UNIMORE), Modena, Italy; and"},{"name":"Ophthalmology Unit- Policlinic of Modena, University of Modena and Reggio Emilia (UNIMORE), Modena, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260717","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R2-20260717","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"R3-20260717","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1001\/archopht.123.11.1570","article-title":"A simplified severity scale for age-related macular degeneration: AREDS report no. 18","volume":"123","author":"Ferris","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R4-20260717","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bjophthalmol-2019-315800","article-title":"Choriocapillaris flow impairment could predict the enlargement of geographic atrophy lesion","volume":"105","author":"Sacconi","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R5-20260717","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"R6-20260717","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/bjophthalmol-2021-318820","article-title":"Characterisation of macular neovascularisation in geographic atrophy","volume":"106","author":"Sacconi","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R7-20260717","first-page":"1","article-title":"Pathogenesis of disciform detachment of the neuroepithelium","volume":"63","author":"Gass","year":"1967","journal-title":"Am J Ophthalmol"},{"key":"R8-20260717","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"R9-20260717","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"R10-20260717","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ophtha.2016.10.036","article-title":"Trends of anti-vascular endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients","volume":"124","author":"Parikh","year":"2017","journal-title":"Ophthalmology"},{"key":"R11-20260717","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/jcm11020325","article-title":"Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression","volume":"11","author":"Veritti","year":"2022","journal-title":"J Clin Med"},{"key":"R12-20260717","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41433-021-01470-9","article-title":"Real-life patient journey in neovascular age-related macular degeneration: a narrative medicine analysis in the Italian setting","volume":"36","author":"Midena","year":"2022","journal-title":"Eye (Lond)"},{"key":"R13-20260717","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40123-022-00631-7","article-title":"The patient voice in neovascular age-related macular degeneration: findings from a qualitative study","volume":"12","author":"Talks","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"R14-20260717","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/13696998.2021.1971416","article-title":"Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data","volume":"24","author":"Korobelnik","year":"2021","journal-title":"J Med Econ"},{"key":"R15-20260717","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40123-025-01104-3","article-title":"Clinical and socioeconomic burden of retinal diseases: can biosimilars add value? A narrative review","volume":"14","author":"Hariprasad","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R16-20260717","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.ophtha.2020.03.031","article-title":"Spectral-domain OCT analysis of risk factors for macular atrophy development in the HARBOR study for neovascular age-related macular degeneration","volume":"127","author":"Sadda","year":"2020","journal-title":"Ophthalmology"},{"key":"R17-20260717","doi-asserted-by":"crossref","first-page":"7194927","DOI":"10.1155\/2017\/7194927","article-title":"Neovascular age-related macular degeneration in the very old (\u226590 years): Epidemiology, adherence to treatment, and comparison of efficacy","volume":"2017","author":"Subhi","year":"2017","journal-title":"J Ophthalmol"},{"key":"R18-20260717","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ajo.2006.11.057","article-title":"Age-related macular degeneration in very old individuals with family history","volume":"143","author":"Geirsdottir","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R19-20260717","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R20-20260717","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ophtha.2009.06.048","article-title":"Antiangiogenic approaches to age-related macular degeneration today","volume":"116","author":"Bressler","year":"2009","journal-title":"Ophthalmology"},{"key":"R21-20260717","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R22-20260717","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":"Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results","volume":"144","author":"Kaiser","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R23-20260717","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","article-title":"Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration","volume":"114","author":"Boyer","year":"2007","journal-title":"Ophthalmology"},{"key":"R24-20260717","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2013.03.009","article-title":"Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration","volume":"59","author":"Finger","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"R25-20260717","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2147\/OPTH.S256009","article-title":"Correlation of baseline visual acuity with outcomes of treatment with Anti-VEGF in neovascular age-related macular degeneration","volume":"14","author":"Veluswamy","year":"2020","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"R26-20260717","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajo.2003.09.042","article-title":"Choroidal neovascularization","volume":"137","author":"Grossniklaus","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R27-20260717","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ophtha.2020.01.040","article-title":"Nonexudative macular neovascularization supporting outer retina in age-related macular degeneration: a clinicopathologic correlation","volume":"127","author":"Chen","year":"2020","journal-title":"Ophthalmology"},{"key":"R28-20260717","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/bjophthalmol-2021-319602","article-title":"Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy","volume":"107","author":"Fang","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"R29-20260717","doi-asserted-by":"crossref","first-page":"101113","DOI":"10.1016\/j.preteyeres.2022.101113","article-title":"Towards a better understanding of non-exudative choroidal and macular neovascularization","volume":"92","author":"Sacconi","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"R30-20260717","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"key":"R31-20260717","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ophtha.2016.01.033","article-title":"Fellow eye comparisons for 7-Year outcomes in ranibizumab-treated AMD subjects from anchor, marina, and horizon (seven-up study)","volume":"123","author":"Bhisitkul","year":"2016","journal-title":"Ophthalmology"},{"key":"R32-20260717","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","article-title":"Macular atrophy progression and 7-year vision outcomes in subjects from the anchor, marina, and horizon studies: the seven-up study","volume":"159","author":"Bhisitkul","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R33-20260717","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in anchor, marina, and horizon: a multicenter cohort study (seven-up)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"R34-20260717","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ophtha.2012.07.076","article-title":"Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration","volume":"120","author":"Kumar","year":"2013","journal-title":"Ophthalmology"},{"key":"R35-20260717","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000433448","article-title":"Quality of life in patients suffering from active exudative age-related macular degeneration: the EQUADE study","volume":"234","author":"Matamoros","year":"2015","journal-title":"Ophthalmologica"},{"key":"R36-20260717","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.3390\/ijms25084433","article-title":"Exploring current molecular targets in the treatment of neovascular age-related macular degeneration toward the perspective of long-term agents","volume":"25","author":"Fragiotta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R37-20260717","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41433-020-01309-9","article-title":"Longer-acting treatments for neovascular age-related macular degeneration-present and future","volume":"35","author":"Iglicki","year":"2021","journal-title":"Eye (Lond)"},{"key":"R38-20260717","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"R39-20260717","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/pharmaceutics15051416","article-title":"Pharmacokinetic and pharmacodynamic rationale for extending VEGF inhibition increasing intravitreal aflibercept dose","volume":"15","author":"Veritti","year":"2023","journal-title":"Pharmaceutics"},{"key":"R40-20260717","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/ICU.0000000000000981","article-title":"Artificial intelligence for home monitoring devices","volume":"34","author":"Keenan","year":"2023","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:01:33Z","timestamp":1784325693000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004837","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}